Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

KATHERINE B REED

Allopathic & Osteopathic Physicians Dermatology

NPI
1396919569
CMS profile
335358
Location
SPOKANE, WA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$547.33

32 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $547.33 32

By paying entity

PY2019 · entire year · sorted by reported total

Page 1 of 1; records 1–32 of 32 matching records. This page contains 32 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

KATHERINE B REED

NPI 1396919569 · CMS profile ID 335358

Allopathic & Osteopathic Physicians / Dermatology

SPOKANE, WA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–32 of 32 matching records. This page contains 32 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1396919569?year=2019&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
KATHERINE B REED, NPI 1396919569, CMS profile ID 335358. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–32 of 32 matching records. This page contains 32 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1396919569?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). KATHERINE B REED, NPI 1396919569, CMS profile ID 335358. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–32 of 32 matching records. This page contains 32 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1396919569?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
KATHERINE B REED, NPI 1396919569, CMS profile ID 335358, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–32 of 32 matching records. This page contains 32 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1396919569?year=2019&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

32 matching records · $547.33 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 32 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–32 of 32.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
GENZYME CORPORATION $15.0711/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694219337 CMS
Lilly USA, LLC $17.4011/04/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657930113 CMS
Novartis Pharmaceuticals Corporation $13.0710/28/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659860567 CMS
Biofrontera Inc. $7.7710/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 690544023 CMS
AbbVie, Inc. $18.9710/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647699319 CMS
Celgene Corporation $23.9408/28/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672886457 CMS
Amgen Inc. $12.1208/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662591459 CMS
Novartis Pharmaceuticals Corporation $17.5708/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659860565 CMS
Lilly USA, LLC $15.8708/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657943901 CMS
AbbVie, Inc. $21.3407/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647699313 CMS
Celgene Corporation $24.3607/24/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672886273 CMS
GENZYME CORPORATION $17.8707/17/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694098869 CMS
Lilly USA, LLC $18.1207/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657950651 CMS
PFIZER INC. $16.4606/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672253685 CMS
AbbVie, Inc. $17.9206/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647699331 CMS
Integra LifeSciences Corporation $25.3306/19/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697158539 CMS
AbbVie, Inc. $15.5206/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647699327 CMS
AbbVie, Inc. $17.0105/30/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647699311 CMS
Novartis Pharmaceuticals Corporation $12.2505/29/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659860563 CMS
PruGen, Inc. Pharmaceuticals $13.5605/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 707764987 CMS
PFIZER INC. $18.4505/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672021947 CMS
Lilly USA, LLC $14.2405/02/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657930111 CMS
AbbVie, Inc. $17.1304/29/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647699353 CMS
Amgen Inc. $13.2104/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662591457 CMS
Helsinn Therapeutics (U.S.), Inc. $15.7804/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 655947391 CMS
AbbVie, Inc. $15.0403/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647699325 CMS
Lilly USA, LLC $17.2003/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657950649 CMS
PFIZER INC. $20.0902/27/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671891609 CMS
Biofrontera Inc. $20.9702/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 667996653 CMS
PFIZER INC. $16.6502/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671853273 CMS
Lilly USA, LLC $19.9101/30/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657926571 CMS
AbbVie, Inc. $17.1401/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647699321 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $547.33 32
PY2020 $413.54 18
PY2021 $570.86 34
PY2022 $538.17 34
PY2023 $498.08 30
PY2024 $705.53 35
PY2025 $1,169.72 67

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $734,267.33 246
PY2024 Principal investigator $853,745.12 356
PY2023 Principal investigator $644,757.85 253
PY2022 Principal investigator $361,336.03 142
PY2021 Principal investigator $277,998.71 117
PY2020 Principal investigator $149,365.00 24
PY2019 Principal investigator $53,682.69 24

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

142 records in PY2022

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Incyte Corporation $2,068.64 12/29/2022 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Children (Ages 2 Years to 12 Years) With Atopic Dermatitis (TRuE-AD3) No dispute reported 06/30/2026 905238625
Principal investigator 1 Incyte Corporation $10,824.84 12/29/2022 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 Followed by an Extension Period in Participants With Vitiligo No dispute reported 06/30/2026 905238627
Principal investigator 1 ABBVIE INC. $2,252.50 12/15/2022 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Study of Oral Upadacitinib Tablet Compared to Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa to Assess Change in Disease Symptoms No dispute reported 06/30/2026 889825339
Principal investigator 1 Incyte Corporation $1,400.00 12/09/2022 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
Topical Ruxolitinib Evaluation in Vitiligo Study 1 (TRuE-V1)A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by an Extension Period in Participants With Vitiligo No dispute reported 06/30/2026 905238629
Principal investigator 1 ABBVIE INC. $2,591.00 12/08/2022 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Study to Assess Adverse Events and Disease Activity With Cedirogant (ABBV-157) in Adult Participants With Moderate to Severe Psoriasis No dispute reported 06/30/2026 889823929
Principal investigator 1 ARENA PHARMACEUTICALS, INC. $6,743.75 12/05/2022 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 24WEEK STUDY WITH A 28WEEK OPENLABEL EXTENSION TO ASSESS THE SAFETY AND EFFICACY OF ETRASIMOD IN SUBJECTS WITH MODERATETOSEVERE ALOPECIA AREATA No dispute reported 06/30/2026 949763425
Principal investigator 1 ARENA PHARMACEUTICALS, INC. $1,901.88 12/05/2022 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 24WEEK STUDY WITH A 28WEEK OPENLABEL EXTENSION TO ASSESS THE SAFETY AND EFFICACY OF ETRASIMOD IN SUBJECTS WITH MODERATETOSEVERE ALOPECIA AREATA No dispute reported 06/30/2026 949763427
Principal investigator 1 Horizon Therapeutics plc $16,749.00 12/05/2022 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE PLLC
A PHASE 2A, OPEN LABEL, PROOF OF CONCEPT TRIAL OF DAXDILIMAB FOR THE TREATMENT OF MODERATE TO SEVERE ALOPECIA AREATA No dispute reported 06/30/2026 937594439
Principal investigator 1 Incyte Corporation $5,493.42 12/01/2022 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Children (Ages 2 Years to 12 Years) With Atopic Dermatitis (TRuE-AD3) No dispute reported 06/30/2026 905238623
Principal investigator 1 ABBVIE INC. $50.00 11/23/2022 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Study to Assess Adverse Events and Disease Activity With Cedirogant (ABBV-157) in Adult Participants With Moderate to Severe Psoriasis No dispute reported 06/30/2026 889821815
Principal investigator 1 ABBVIE INC. $1,702.00 11/22/2022 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Study to Assess Adverse Events and Disease Activity With Cedirogant (ABBV-157) in Adult Participants With Moderate to Severe Psoriasis No dispute reported 06/30/2026 889821671
Principal investigator 1 ABBVIE INC. $471.00 11/11/2022 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Study of Oral Upadacitinib Tablet Compared to Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa to Assess Change in Disease Symptoms No dispute reported 06/30/2026 889820711
Principal investigator 1 Incyte Corporation $232.85 11/10/2022 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Children (Ages 2 Years to 12 Years) With Atopic Dermatitis (TRuE-AD3) No dispute reported 06/30/2026 905238617
Principal investigator 1 ARENA PHARMACEUTICALS, INC. $60.94 11/07/2022 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 24WEEK STUDY WITH A 28WEEK OPENLABEL EXTENSION TO ASSESS THE SAFETY AND EFFICACY OF ETRASIMOD IN SUBJECTS WITH MODERATETOSEVERE ALOPECIA AREATA No dispute reported 06/30/2026 949763277
Principal investigator 1 ARENA PHARMACEUTICALS, INC. $475.00 11/07/2022 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 24WEEK STUDY WITH A 28WEEK OPENLABEL EXTENSION TO ASSESS THE SAFETY AND EFFICACY OF ETRASIMOD IN SUBJECTS WITH MODERATETOSEVERE ALOPECIA AREATA No dispute reported 06/30/2026 949763429
Principal investigator 1 ARENA PHARMACEUTICALS, INC. $9,190.63 11/07/2022 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 24WEEK STUDY WITH A 28WEEK OPENLABEL EXTENSION TO ASSESS THE SAFETY AND EFFICACY OF ETRASIMOD IN SUBJECTS WITH MODERATETOSEVERE ALOPECIA AREATA No dispute reported 06/30/2026 949763487
Principal investigator 1 ARENA PHARMACEUTICALS, INC. $5,792.00 11/07/2022 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 24WEEK STUDY WITH A 28WEEK OPENLABEL EXTENSION TO ASSESS THE SAFETY AND EFFICACY OF ETRASIMOD IN SUBJECTS WITH MODERATETOSEVERE ALOPECIA AREATA No dispute reported 06/30/2026 949763491
Principal investigator 1 ARENA PHARMACEUTICALS, INC. $2,677.50 11/07/2022 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 24WEEK STUDY WITH A 28WEEK OPENLABEL EXTENSION TO ASSESS THE SAFETY AND EFFICACY OF ETRASIMOD IN SUBJECTS WITH MODERATETOSEVERE ALOPECIA AREATA No dispute reported 06/30/2026 949764983
Principal investigator 1 ARENA PHARMACEUTICALS, INC. $1,232.50 11/07/2022 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 24WEEK STUDY WITH A 28WEEK OPENLABEL EXTENSION TO ASSESS THE SAFETY AND EFFICACY OF ETRASIMOD IN SUBJECTS WITH MODERATETOSEVERE ALOPECIA AREATA No dispute reported 06/30/2026 949765085
Principal investigator 1 ARENA PHARMACEUTICALS, INC. $2,677.50 11/07/2022 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 24WEEK STUDY WITH A 28WEEK OPENLABEL EXTENSION TO ASSESS THE SAFETY AND EFFICACY OF ETRASIMOD IN SUBJECTS WITH MODERATETOSEVERE ALOPECIA AREATA No dispute reported 06/30/2026 949765141
Principal investigator 1 ARENA PHARMACEUTICALS, INC. $1,232.50 11/07/2022 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 24WEEK STUDY WITH A 28WEEK OPENLABEL EXTENSION TO ASSESS THE SAFETY AND EFFICACY OF ETRASIMOD IN SUBJECTS WITH MODERATETOSEVERE ALOPECIA AREATA No dispute reported 06/30/2026 949765243
Principal investigator 1 ARENA PHARMACEUTICALS, INC. $1,370.63 11/07/2022 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 24WEEK STUDY WITH A 28WEEK OPENLABEL EXTENSION TO ASSESS THE SAFETY AND EFFICACY OF ETRASIMOD IN SUBJECTS WITH MODERATETOSEVERE ALOPECIA AREATA No dispute reported 06/30/2026 949765503
Principal investigator 1 Incyte Corporation $4,381.16 11/03/2022 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Children (Ages 2 Years to 12 Years) With Atopic Dermatitis (TRuE-AD3) No dispute reported 06/30/2026 905238619
Principal investigator 1 Incyte Corporation $5,267.58 11/03/2022 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Randomized, Double-Blind, Vehicle-Controlled Study to Evaluate the Mechanism of Action of Ruxolitinib Cream for Vitiligo No dispute reported 06/30/2026 905238621
Principal investigator 1 ABBVIE INC. $3,935.60 10/14/2022 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Study to Assess Adverse Events and Disease Activity With Cedirogant (ABBV-157) in Adult Participants With Moderate to Severe Psoriasis No dispute reported 06/30/2026 889816567
Principal investigator 1 ARENA PHARMACEUTICALS, INC. $2,745.50 10/11/2022 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 24WEEK STUDY WITH A 28WEEK OPENLABEL EXTENSION TO ASSESS THE SAFETY AND EFFICACY OF ETRASIMOD IN SUBJECTS WITH MODERATETOSEVERE ALOPECIA AREATA No dispute reported 06/30/2026 949763489
Principal investigator 1 ARENA PHARMACEUTICALS, INC. $374.00 10/11/2022 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 24WEEK STUDY WITH A 28WEEK OPENLABEL EXTENSION TO ASSESS THE SAFETY AND EFFICACY OF ETRASIMOD IN SUBJECTS WITH MODERATETOSEVERE ALOPECIA AREATA No dispute reported 06/30/2026 949765255
Principal investigator 1 ARENA PHARMACEUTICALS, INC. $998.75 10/11/2022 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 24WEEK STUDY WITH A 28WEEK OPENLABEL EXTENSION TO ASSESS THE SAFETY AND EFFICACY OF ETRASIMOD IN SUBJECTS WITH MODERATETOSEVERE ALOPECIA AREATA No dispute reported 06/30/2026 949765351
Principal investigator 1 ARENA PHARMACEUTICALS, INC. $374.00 10/11/2022 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 24WEEK STUDY WITH A 28WEEK OPENLABEL EXTENSION TO ASSESS THE SAFETY AND EFFICACY OF ETRASIMOD IN SUBJECTS WITH MODERATETOSEVERE ALOPECIA AREATA No dispute reported 06/30/2026 949765403
Principal investigator 1 ARENA PHARMACEUTICALS, INC. $998.75 10/11/2022 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 24WEEK STUDY WITH A 28WEEK OPENLABEL EXTENSION TO ASSESS THE SAFETY AND EFFICACY OF ETRASIMOD IN SUBJECTS WITH MODERATETOSEVERE ALOPECIA AREATA No dispute reported 06/30/2026 949765453
Principal investigator 1 Almirall LLC $2,757.84 10/11/2022 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
M14867-32 No dispute reported 06/30/2026 902933293
Principal investigator 1 Incyte Corporation $4,041.98 10/05/2022 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Children (Ages 2 Years to 12 Years) With Atopic Dermatitis (TRuE-AD3) No dispute reported 06/30/2026 905238615
Principal investigator 1 ARENA PHARMACEUTICALS, INC. $12,395.00 10/03/2022 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 24WEEK STUDY WITH A 28WEEK OPENLABEL EXTENSION TO ASSESS THE SAFETY AND EFFICACY OF ETRASIMOD IN SUBJECTS WITH MODERATETOSEVERE ALOPECIA AREATA No dispute reported 06/30/2026 949763619
Principal investigator 1 Incyte Corporation $1,200.00 09/22/2022 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 Followed by an Extension Period in Participants With Vitiligo No dispute reported 06/30/2026 905238561
Principal investigator 1 ARENA PHARMACEUTICALS, INC. $950.94 09/12/2022 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 24WEEK STUDY WITH A 28WEEK OPENLABEL EXTENSION TO ASSESS THE SAFETY AND EFFICACY OF ETRASIMOD IN SUBJECTS WITH MODERATETOSEVERE ALOPECIA AREATA No dispute reported 06/30/2026 949764937
Principal investigator 1 ARENA PHARMACEUTICALS, INC. $2,677.50 09/12/2022 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 24WEEK STUDY WITH A 28WEEK OPENLABEL EXTENSION TO ASSESS THE SAFETY AND EFFICACY OF ETRASIMOD IN SUBJECTS WITH MODERATETOSEVERE ALOPECIA AREATA No dispute reported 06/30/2026 949765295
Principal investigator 1 ARENA PHARMACEUTICALS, INC. $950.94 09/12/2022 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 24WEEK STUDY WITH A 28WEEK OPENLABEL EXTENSION TO ASSESS THE SAFETY AND EFFICACY OF ETRASIMOD IN SUBJECTS WITH MODERATETOSEVERE ALOPECIA AREATA No dispute reported 06/30/2026 949765413
Principal investigator 1 ARENA PHARMACEUTICALS, INC. $1,232.50 09/12/2022 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 24WEEK STUDY WITH A 28WEEK OPENLABEL EXTENSION TO ASSESS THE SAFETY AND EFFICACY OF ETRASIMOD IN SUBJECTS WITH MODERATETOSEVERE ALOPECIA AREATA No dispute reported 06/30/2026 949765499
Principal investigator 1 ARENA PHARMACEUTICALS, INC. $950.94 09/12/2022 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 24WEEK STUDY WITH A 28WEEK OPENLABEL EXTENSION TO ASSESS THE SAFETY AND EFFICACY OF ETRASIMOD IN SUBJECTS WITH MODERATETOSEVERE ALOPECIA AREATA No dispute reported 06/30/2026 949766449
Principal investigator 1 ARENA PHARMACEUTICALS, INC. $374.00 09/12/2022 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 24WEEK STUDY WITH A 28WEEK OPENLABEL EXTENSION TO ASSESS THE SAFETY AND EFFICACY OF ETRASIMOD IN SUBJECTS WITH MODERATETOSEVERE ALOPECIA AREATA No dispute reported 06/30/2026 949766453
Principal investigator 1 Almirall LLC $4,079.16 09/12/2022 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
M14867-32 No dispute reported 06/30/2026 902933231
Principal investigator 1 Almirall LLC $1,100.00 09/12/2022 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
M14867-32 No dispute reported 06/30/2026 902933233
Principal investigator 1 Incyte Corporation $630.00 09/08/2022 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Randomized, Double-Blind, Vehicle-Controlled Study to Evaluate the Mechanism of Action of Ruxolitinib Cream for Vitiligo No dispute reported 06/30/2026 905238553
Principal investigator 1 Kiniksa Pharmaceuticals, Ltd. $5,250.00 09/07/2022 Non-covered Recipient Entity
Dermatology Specialist of Spokane
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 949998151
Principal investigator 1 Incyte Corporation $855.00 09/02/2022 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Children (Ages 2 Years to 12 Years) With Atopic Dermatitis (TRuE-AD3) No dispute reported 06/30/2026 905238555
Principal investigator 1 Incyte Corporation $8,786.70 09/02/2022 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 Followed by an Extension Period in Participants With Vitiligo No dispute reported 06/30/2026 905238557
Principal investigator 1 Incyte Corporation $1,080.00 09/02/2022 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 Followed by an Extension Period in Participants With Vitiligo No dispute reported 06/30/2026 905238559
Principal investigator 1 Incyte Corporation $717.25 09/02/2022 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Safety and Efficacy Study of Ruxolitinib Cream Combined With Narrow-Band Ultraviolet B Phototherapy in Participants With Vitiligo No dispute reported 06/30/2026 905238563
Principal investigator 1 Incyte Corporation $1,458.99 08/26/2022 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Randomized, Double-Blind, Vehicle-Controlled Study to Evaluate the Mechanism of Action of Ruxolitinib Cream for Vitiligo No dispute reported 06/30/2026 905238545
Principal investigator 1 Incyte Corporation $13,767.02 08/26/2022 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Children (Ages 2 Years to 12 Years) With Atopic Dermatitis (TRuE-AD3) No dispute reported 06/30/2026 905238549
Principal investigator 1 Incyte Corporation $181.00 08/26/2022 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Safety and Efficacy Study of Ruxolitinib Cream Combined With Narrow-Band Ultraviolet B Phototherapy in Participants With Vitiligo No dispute reported 06/30/2026 905238551
Principal investigator 1 Kiniksa Pharmaceuticals, Ltd. $300.00 08/24/2022 Non-covered Recipient Entity
Dermatology Specialist of Spokane
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 949998153
Principal investigator 1 Kiniksa Pharmaceuticals, Ltd. $1,650.00 08/24/2022 Non-covered Recipient Entity
Dermatology Specialist of Spokane
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 949998155
Principal investigator 1 Kiniksa Pharmaceuticals, Ltd. $140.68 08/12/2022 Non-covered Recipient Entity
Dermatology Specialist of Spokane
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 949998145
Principal investigator 1 Kiniksa Pharmaceuticals, Ltd. $217.62 08/12/2022 Non-covered Recipient Entity
Dermatology Specialist of Spokane
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 949998147
Principal investigator 1 Kiniksa Pharmaceuticals, Ltd. $300.00 08/12/2022 Non-covered Recipient Entity
Dermatology Specialist of Spokane
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 949998169
Principal investigator 1 Kiniksa Pharmaceuticals, Ltd. $1,650.00 08/12/2022 Non-covered Recipient Entity
Dermatology Specialist of Spokane
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 949998171
Principal investigator 1 ARENA PHARMACEUTICALS, INC. $1,317.50 08/09/2022 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 24WEEK STUDY WITH A 28WEEK OPENLABEL EXTENSION TO ASSESS THE SAFETY AND EFFICACY OF ETRASIMOD IN SUBJECTS WITH MODERATETOSEVERE ALOPECIA AREATA No dispute reported 06/30/2026 949765083
Principal investigator 1 ARENA PHARMACEUTICALS, INC. $374.00 08/09/2022 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 24WEEK STUDY WITH A 28WEEK OPENLABEL EXTENSION TO ASSESS THE SAFETY AND EFFICACY OF ETRASIMOD IN SUBJECTS WITH MODERATETOSEVERE ALOPECIA AREATA No dispute reported 06/30/2026 949765143
Principal investigator 1 ARENA PHARMACEUTICALS, INC. $1,700.00 08/09/2022 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 24WEEK STUDY WITH A 28WEEK OPENLABEL EXTENSION TO ASSESS THE SAFETY AND EFFICACY OF ETRASIMOD IN SUBJECTS WITH MODERATETOSEVERE ALOPECIA AREATA No dispute reported 06/30/2026 949765193
Principal investigator 1 ARENA PHARMACEUTICALS, INC. $536.56 08/09/2022 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 24WEEK STUDY WITH A 28WEEK OPENLABEL EXTENSION TO ASSESS THE SAFETY AND EFFICACY OF ETRASIMOD IN SUBJECTS WITH MODERATETOSEVERE ALOPECIA AREATA No dispute reported 06/30/2026 949765197
Principal investigator 1 ARENA PHARMACEUTICALS, INC. $1,700.00 08/09/2022 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 24WEEK STUDY WITH A 28WEEK OPENLABEL EXTENSION TO ASSESS THE SAFETY AND EFFICACY OF ETRASIMOD IN SUBJECTS WITH MODERATETOSEVERE ALOPECIA AREATA No dispute reported 06/30/2026 949765553
Principal investigator 1 Almirall LLC $6,000.00 08/09/2022 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
M14867-32 No dispute reported 06/30/2026 902933167
Principal investigator 1 Incyte Corporation $1,117.66 08/02/2022 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Children (Ages 2 Years to 12 Years) With Atopic Dermatitis (TRuE-AD3) No dispute reported 06/30/2026 905238547
Principal investigator 1 ARENA PHARMACEUTICALS, INC. $950.94 06/30/2022 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 24WEEK STUDY WITH A 28WEEK OPENLABEL EXTENSION TO ASSESS THE SAFETY AND EFFICACY OF ETRASIMOD IN SUBJECTS WITH MODERATETOSEVERE ALOPECIA AREATA No dispute reported 06/30/2026 949765207
Principal investigator 1 ARENA PHARMACEUTICALS, INC. $536.56 06/30/2022 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 24WEEK STUDY WITH A 28WEEK OPENLABEL EXTENSION TO ASSESS THE SAFETY AND EFFICACY OF ETRASIMOD IN SUBJECTS WITH MODERATETOSEVERE ALOPECIA AREATA No dispute reported 06/30/2026 949765247
Principal investigator 1 ARENA PHARMACEUTICALS, INC. $675.00 06/30/2022 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 24WEEK STUDY WITH A 28WEEK OPENLABEL EXTENSION TO ASSESS THE SAFETY AND EFFICACY OF ETRASIMOD IN SUBJECTS WITH MODERATETOSEVERE ALOPECIA AREATA No dispute reported 06/30/2026 949765399
Principal investigator 1 ARENA PHARMACEUTICALS, INC. $1,317.50 06/30/2022 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 24WEEK STUDY WITH A 28WEEK OPENLABEL EXTENSION TO ASSESS THE SAFETY AND EFFICACY OF ETRASIMOD IN SUBJECTS WITH MODERATETOSEVERE ALOPECIA AREATA No dispute reported 06/30/2026 949765411
Principal investigator 1 ARENA PHARMACEUTICALS, INC. $950.94 06/30/2022 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 24WEEK STUDY WITH A 28WEEK OPENLABEL EXTENSION TO ASSESS THE SAFETY AND EFFICACY OF ETRASIMOD IN SUBJECTS WITH MODERATETOSEVERE ALOPECIA AREATA No dispute reported 06/30/2026 949765451
Principal investigator 1 ARENA PHARMACEUTICALS, INC. $200.00 06/30/2022 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 24WEEK STUDY WITH A 28WEEK OPENLABEL EXTENSION TO ASSESS THE SAFETY AND EFFICACY OF ETRASIMOD IN SUBJECTS WITH MODERATETOSEVERE ALOPECIA AREATA No dispute reported 06/30/2026 949765455
Principal investigator 1 ARENA PHARMACEUTICALS, INC. $950.94 06/30/2022 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 24WEEK STUDY WITH A 28WEEK OPENLABEL EXTENSION TO ASSESS THE SAFETY AND EFFICACY OF ETRASIMOD IN SUBJECTS WITH MODERATETOSEVERE ALOPECIA AREATA No dispute reported 06/30/2026 949765501
Principal investigator 1 ARENA PHARMACEUTICALS, INC. $998.75 06/30/2022 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 24WEEK STUDY WITH A 28WEEK OPENLABEL EXTENSION TO ASSESS THE SAFETY AND EFFICACY OF ETRASIMOD IN SUBJECTS WITH MODERATETOSEVERE ALOPECIA AREATA No dispute reported 06/30/2026 949765551
Principal investigator 1 Incyte Corporation $1,159.47 06/24/2022 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Randomized, Double-Blind, Vehicle-Controlled Study to Evaluate the Mechanism of Action of Ruxolitinib Cream for Vitiligo No dispute reported 06/30/2026 905238539
Principal investigator 1 Incyte Corporation $1,998.79 06/24/2022 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Children (Ages 2 Years to 12 Years) With Atopic Dermatitis (TRuE-AD3) No dispute reported 06/30/2026 905238543
Principal investigator 1 ABBVIE INC. $3,000.00 06/23/2022 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Study of Oral Upadacitinib Tablet Compared to Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa to Assess Change in Disease Symptoms No dispute reported 06/30/2026 889796911
Principal investigator 1 ABBVIE INC. $408.00 06/23/2022 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Study of Oral Upadacitinib Tablet Compared to Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa to Assess Change in Disease Symptoms No dispute reported 06/30/2026 889797059
Principal investigator 1 Kiniksa Pharmaceuticals, Ltd. $3,672.00 06/17/2022 Non-covered Recipient Entity
Dermatology Specialist of Spokane
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 949998129
Principal investigator 1 Kiniksa Pharmaceuticals, Ltd. $2,561.62 06/17/2022 Non-covered Recipient Entity
Dermatology Specialist of Spokane
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 949998131
Principal investigator 1 Kiniksa Pharmaceuticals, Ltd. $568.75 06/13/2022 Non-covered Recipient Entity
Dermatology Specialist of Spokane
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 949998125
Principal investigator 1 Kiniksa Pharmaceuticals, Ltd. $1,708.75 06/13/2022 Non-covered Recipient Entity
Dermatology Specialist of Spokane
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 949998127
Principal investigator 1 Kiniksa Pharmaceuticals, Ltd. $568.75 06/13/2022 Non-covered Recipient Entity
Dermatology Specialist of Spokane
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 949998185
Principal investigator 1 Incyte Corporation $1,000.00 06/10/2022 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Children (Ages 2 Years to 12 Years) With Atopic Dermatitis (TRuE-AD3) No dispute reported 06/30/2026 905238541
Principal investigator 1 ARENA PHARMACEUTICALS, INC. $903.13 06/07/2022 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 24WEEK STUDY WITH A 28WEEK OPENLABEL EXTENSION TO ASSESS THE SAFETY AND EFFICACY OF ETRASIMOD IN SUBJECTS WITH MODERATETOSEVERE ALOPECIA AREATA No dispute reported 06/30/2026 949764939
Principal investigator 1 ARENA PHARMACEUTICALS, INC. $1,184.69 06/07/2022 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 24WEEK STUDY WITH A 28WEEK OPENLABEL EXTENSION TO ASSESS THE SAFETY AND EFFICACY OF ETRASIMOD IN SUBJECTS WITH MODERATETOSEVERE ALOPECIA AREATA No dispute reported 06/30/2026 949764941
Principal investigator 1 ARENA PHARMACEUTICALS, INC. $4,547.50 06/07/2022 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 24WEEK STUDY WITH A 28WEEK OPENLABEL EXTENSION TO ASSESS THE SAFETY AND EFFICACY OF ETRASIMOD IN SUBJECTS WITH MODERATETOSEVERE ALOPECIA AREATA No dispute reported 06/30/2026 949765205
Principal investigator 1 ARENA PHARMACEUTICALS, INC. $536.56 06/07/2022 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 24WEEK STUDY WITH A 28WEEK OPENLABEL EXTENSION TO ASSESS THE SAFETY AND EFFICACY OF ETRASIMOD IN SUBJECTS WITH MODERATETOSEVERE ALOPECIA AREATA No dispute reported 06/30/2026 949765209
Principal investigator 1 ARENA PHARMACEUTICALS, INC. $536.56 06/07/2022 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 24WEEK STUDY WITH A 28WEEK OPENLABEL EXTENSION TO ASSESS THE SAFETY AND EFFICACY OF ETRASIMOD IN SUBJECTS WITH MODERATETOSEVERE ALOPECIA AREATA No dispute reported 06/30/2026 949765245
Principal investigator 1 ARENA PHARMACEUTICALS, INC. $950.94 06/07/2022 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 24WEEK STUDY WITH A 28WEEK OPENLABEL EXTENSION TO ASSESS THE SAFETY AND EFFICACY OF ETRASIMOD IN SUBJECTS WITH MODERATETOSEVERE ALOPECIA AREATA No dispute reported 06/30/2026 949765257
Principal investigator 1 ARENA PHARMACEUTICALS, INC. $1,673.44 06/07/2022 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 24WEEK STUDY WITH A 28WEEK OPENLABEL EXTENSION TO ASSESS THE SAFETY AND EFFICACY OF ETRASIMOD IN SUBJECTS WITH MODERATETOSEVERE ALOPECIA AREATA No dispute reported 06/30/2026 949765291
Principal investigator 1 ARENA PHARMACEUTICALS, INC. $1,673.44 06/07/2022 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 24WEEK STUDY WITH A 28WEEK OPENLABEL EXTENSION TO ASSESS THE SAFETY AND EFFICACY OF ETRASIMOD IN SUBJECTS WITH MODERATETOSEVERE ALOPECIA AREATA No dispute reported 06/30/2026 949765293
Principal investigator 1 ARENA PHARMACEUTICALS, INC. $1,184.69 06/07/2022 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 24WEEK STUDY WITH A 28WEEK OPENLABEL EXTENSION TO ASSESS THE SAFETY AND EFFICACY OF ETRASIMOD IN SUBJECTS WITH MODERATETOSEVERE ALOPECIA AREATA No dispute reported 06/30/2026 949765347
Principal investigator 1 ARENA PHARMACEUTICALS, INC. $4,547.50 06/07/2022 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 24WEEK STUDY WITH A 28WEEK OPENLABEL EXTENSION TO ASSESS THE SAFETY AND EFFICACY OF ETRASIMOD IN SUBJECTS WITH MODERATETOSEVERE ALOPECIA AREATA No dispute reported 06/30/2026 949765349
Principal investigator 1 ARENA PHARMACEUTICALS, INC. $1,317.50 06/07/2022 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 24WEEK STUDY WITH A 28WEEK OPENLABEL EXTENSION TO ASSESS THE SAFETY AND EFFICACY OF ETRASIMOD IN SUBJECTS WITH MODERATETOSEVERE ALOPECIA AREATA No dispute reported 06/30/2026 949765401
Principal investigator 1 ARENA PHARMACEUTICALS, INC. $950.94 06/07/2022 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 24WEEK STUDY WITH A 28WEEK OPENLABEL EXTENSION TO ASSESS THE SAFETY AND EFFICACY OF ETRASIMOD IN SUBJECTS WITH MODERATETOSEVERE ALOPECIA AREATA No dispute reported 06/30/2026 949765415
Principal investigator 1 ARENA PHARMACEUTICALS, INC. $1,700.00 06/07/2022 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 24WEEK STUDY WITH A 28WEEK OPENLABEL EXTENSION TO ASSESS THE SAFETY AND EFFICACY OF ETRASIMOD IN SUBJECTS WITH MODERATETOSEVERE ALOPECIA AREATA No dispute reported 06/30/2026 949765555
Principal investigator 1 ARENA PHARMACEUTICALS, INC. $903.13 06/07/2022 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 24WEEK STUDY WITH A 28WEEK OPENLABEL EXTENSION TO ASSESS THE SAFETY AND EFFICACY OF ETRASIMOD IN SUBJECTS WITH MODERATETOSEVERE ALOPECIA AREATA No dispute reported 06/30/2026 949766451
Principal investigator 1 Incyte Corporation $4,064.85 05/31/2022 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Children (Ages 2 Years to 12 Years) With Atopic Dermatitis (TRuE-AD3) No dispute reported 06/30/2026 905238527
Principal investigator 1 Incyte Corporation $3,355.56 05/31/2022 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 Followed by an Extension Period in Participants With Vitiligo No dispute reported 06/30/2026 905238537
Principal investigator 1 Incyte Corporation $1,750.00 05/13/2022 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Double-Blind, Vehicle-Controlled, Randomized Withdrawal and Treatment Extension Study to Assess the Long-Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo No dispute reported 06/30/2026 905238533
Principal investigator 1 ARENA PHARMACEUTICALS, INC. $1,673.44 05/10/2022 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 24WEEK STUDY WITH A 28WEEK OPENLABEL EXTENSION TO ASSESS THE SAFETY AND EFFICACY OF ETRASIMOD IN SUBJECTS WITH MODERATETOSEVERE ALOPECIA AREATA No dispute reported 06/30/2026 949765139
Principal investigator 1 ARENA PHARMACEUTICALS, INC. $950.94 05/10/2022 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 24WEEK STUDY WITH A 28WEEK OPENLABEL EXTENSION TO ASSESS THE SAFETY AND EFFICACY OF ETRASIMOD IN SUBJECTS WITH MODERATETOSEVERE ALOPECIA AREATA No dispute reported 06/30/2026 949765195
Principal investigator 1 Incyte Corporation $1,298.00 05/06/2022 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Double-Blind, Vehicle-Controlled, Randomized Withdrawal and Treatment Extension Study to Assess the Long-Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo No dispute reported 06/30/2026 905238531
Principal investigator 1 Incyte Corporation $3,095.82 05/03/2022 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Randomized, Double-Blind, Vehicle-Controlled Study to Evaluate the Mechanism of Action of Ruxolitinib Cream for Vitiligo No dispute reported 06/30/2026 905238523
Principal investigator 1 Incyte Corporation $5,260.47 05/03/2022 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Children (Ages 2 Years to 12 Years) With Atopic Dermatitis (TRuE-AD3) No dispute reported 06/30/2026 905238525
Principal investigator 1 Incyte Corporation $1,389.37 05/03/2022 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Double-Blind, Vehicle-Controlled, Randomized Withdrawal and Treatment Extension Study to Assess the Long-Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo No dispute reported 06/30/2026 905238529
Principal investigator 1 Incyte Corporation $5,212.35 05/03/2022 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 Followed by an Extension Period in Participants With Vitiligo No dispute reported 06/30/2026 905238535
Principal investigator 1 Kiniksa Pharmaceuticals, Ltd. $5,395.50 04/26/2022 Non-covered Recipient Entity
Dermatology Specialist of Spokane
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 949998123
Principal investigator 1 ABBVIE INC. $1,612.75 04/21/2022 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Study of Oral Upadacitinib Tablet Compared to Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa to Assess Change in Disease Symptoms No dispute reported 06/30/2026 889787915
Principal investigator 1 Incyte Corporation $525.00 04/15/2022 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 Followed by an Extension Period in Participants With Vitiligo No dispute reported 06/30/2026 905238495
Principal investigator 1 ABBVIE INC. $8,400.00 04/14/2022 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Study to Assess Adverse Events and Disease Activity With Cedirogant (ABBV-157) in Adult Participants With Moderate to Severe Psoriasis No dispute reported 06/30/2026 889786177
Principal investigator 1 Kiniksa Pharmaceuticals, Ltd. $20,682.00 04/14/2022 Non-covered Recipient Entity
Dermatology Specialist of Spokane
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 949998121
Principal investigator 1 ARENA PHARMACEUTICALS, INC. $740.00 04/05/2022 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 24WEEK STUDY WITH A 28WEEK OPENLABEL EXTENSION TO ASSESS THE SAFETY AND EFFICACY OF ETRASIMOD IN SUBJECTS WITH MODERATETOSEVERE ALOPECIA AREATA No dispute reported 06/30/2026 949765259
Principal investigator 1 Kiniksa Pharmaceuticals, Ltd. $12.89 04/05/2022 Non-covered Recipient Entity
Dermatology Specialist of Spokane
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 949998119
Principal investigator 1 Incyte Corporation $525.00 04/01/2022 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Children (Ages 2 Years to 12 Years) With Atopic Dermatitis (TRuE-AD3) No dispute reported 06/30/2026 905238493
Principal investigator 1 ARENA PHARMACEUTICALS, INC. $4,440.00 03/29/2022 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 24WEEK STUDY WITH A 28WEEK OPENLABEL EXTENSION TO ASSESS THE SAFETY AND EFFICACY OF ETRASIMOD IN SUBJECTS WITH MODERATETOSEVERE ALOPECIA AREATA No dispute reported 06/30/2026 949765087
Principal investigator 1 Incyte Corporation $750.00 03/25/2022 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Randomized, Double-Blind, Vehicle-Controlled Study to Evaluate the Mechanism of Action of Ruxolitinib Cream for Vitiligo No dispute reported 06/30/2026 905238511
Principal investigator 1 Incyte Corporation $7,019.00 03/25/2022 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Safety and Efficacy Study of Ruxolitinib Cream Combined With Narrow-Band Ultraviolet B Phototherapy in Participants With Vitiligo No dispute reported 06/30/2026 905238513
Principal investigator 1 Incyte Corporation $4,641.74 03/25/2022 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Double-Blind, Vehicle-Controlled, Randomized Withdrawal and Treatment Extension Study to Assess the Long-Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo No dispute reported 06/30/2026 905238515
Principal investigator 1 Incyte Corporation $3,006.90 03/25/2022 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 Followed by an Extension Period in Participants With Vitiligo No dispute reported 06/30/2026 905238517
Principal investigator 1 Incyte Corporation $30.95 03/04/2022 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Randomized, Double-Blind, Vehicle-Controlled Study to Evaluate the Mechanism of Action of Ruxolitinib Cream for Vitiligo No dispute reported 06/30/2026 905238509
Principal investigator 1 Kiniksa Pharmaceuticals, Ltd. $351.70 03/03/2022 Non-covered Recipient Entity
Dermatology Specialist of Spokane
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 949998105
Principal investigator 1 Kiniksa Pharmaceuticals, Ltd. $32.00 03/01/2022 Non-covered Recipient Entity
Dermatology Specialist of Spokane
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 949998107
Principal investigator 1 Incyte Corporation $3,777.93 02/25/2022 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Randomized, Double-Blind, Vehicle-Controlled Study to Evaluate the Mechanism of Action of Ruxolitinib Cream for Vitiligo No dispute reported 06/30/2026 905238499
Principal investigator 1 Incyte Corporation $5,218.80 02/25/2022 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Children (Ages 2 Years to 12 Years) With Atopic Dermatitis (TRuE-AD3) No dispute reported 06/30/2026 905238501
Principal investigator 1 Incyte Corporation $450.00 02/25/2022 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
Topical Ruxolitinib Evaluation in Vitiligo Study 1 (TRuE-V1)A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by an Extension Period in Participants With Vitiligo No dispute reported 06/30/2026 905238503
Principal investigator 1 Kiniksa Pharmaceuticals, Ltd. $362.70 02/23/2022 Non-covered Recipient Entity
Dermatology Specialist of Spokane
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 949998095
Principal investigator 1 Kiniksa Pharmaceuticals, Ltd. $351.70 02/23/2022 Non-covered Recipient Entity
Dermatology Specialist of Spokane
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 949998097
Principal investigator 1 Kiniksa Pharmaceuticals, Ltd. $247.30 02/23/2022 Non-covered Recipient Entity
Dermatology Specialist of Spokane
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 949998099
Principal investigator 1 Kiniksa Pharmaceuticals, Ltd. $197.84 02/23/2022 Non-covered Recipient Entity
Dermatology Specialist of Spokane
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 949998101
Principal investigator 1 Kiniksa Pharmaceuticals, Ltd. $108.88 02/23/2022 Non-covered Recipient Entity
Dermatology Specialist of Spokane
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 949998103
Principal investigator 1 Kiniksa Pharmaceuticals, Ltd. $8,370.00 02/10/2022 Non-covered Recipient Entity
Dermatology Specialist of Spokane
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 949998111
Principal investigator 1 ABBVIE INC. $1,699.25 02/08/2022 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Study of Oral Upadacitinib Tablet Compared to Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa to Assess Change in Disease Symptoms No dispute reported 06/30/2026 889776253
Principal investigator 1 Kiniksa Pharmaceuticals, Ltd. $2,145.37 02/01/2022 Non-covered Recipient Entity
Dermatology Specialist of Spokane
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 949998109
Principal investigator 1 Incyte Corporation $1,636.83 01/28/2022 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Randomized, Double-Blind, Vehicle-Controlled Study to Evaluate the Mechanism of Action of Ruxolitinib Cream for Vitiligo No dispute reported 06/30/2026 905238483
Principal investigator 1 Incyte Corporation $3,726.00 01/28/2022 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Double-Blind, Vehicle-Controlled, Randomized Withdrawal and Treatment Extension Study to Assess the Long-Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo No dispute reported 06/30/2026 905238485
Principal investigator 1 Incyte Corporation $4,336.02 01/28/2022 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 Followed by an Extension Period in Participants With Vitiligo No dispute reported 06/30/2026 905238487
Principal investigator 1 Incyte Corporation $13,360.11 01/28/2022 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
Topical Ruxolitinib Evaluation in Vitiligo Study 1 (TRuE-V1)A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by an Extension Period in Participants With Vitiligo No dispute reported 06/30/2026 905238489
Principal investigator 1 Kiniksa Pharmaceuticals, Ltd. $44.98 01/21/2022 Non-covered Recipient Entity
Dermatology Specialist of Spokane
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 949997905
Principal investigator 1 Kiniksa Pharmaceuticals, Ltd. $49.46 01/21/2022 Non-covered Recipient Entity
Dermatology Specialist of Spokane
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 949997907
Principal investigator 1 Kiniksa Pharmaceuticals, Ltd. $6.25 01/21/2022 Non-covered Recipient Entity
Dermatology Specialist of Spokane
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 949997909
Principal investigator 1 Kiniksa Pharmaceuticals, Ltd. $38.40 01/21/2022 Non-covered Recipient Entity
Dermatology Specialist of Spokane
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 949997911
Principal investigator 1 Incyte Corporation $4,449.00 01/07/2022 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
Topical Ruxolitinib Evaluation in Vitiligo Study 1 (TRuE-V1)A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by an Extension Period in Participants With Vitiligo No dispute reported 06/30/2026 905238481